Metabolomics profiling predicts outcome of tocilizumab in rheumatoid arthritis: an exploratory study.
Jessica D Murillo-SaichCesar Diaz-TornéMaría Angels OrtizRoxana CorasPaulo Vinicius Gil AlabarseAnders Bay NordHèctor CorominasSilvia VidalMónica GumaPublished in: Metabolomics : Official journal of the Metabolomic Society (2021)
The relationship between plasma metabolic profiles and the clinical response to tocilizumab suggests that 1H-NMR may be a promising tool for RA therapy optimization. More studies are needed to determine if metabolic profiling can predict the response to biological therapies in RA patients.
Keyphrases
- rheumatoid arthritis
- disease activity
- end stage renal disease
- ankylosing spondylitis
- interstitial lung disease
- rheumatoid arthritis patients
- ejection fraction
- newly diagnosed
- chronic kidney disease
- single cell
- mass spectrometry
- prognostic factors
- stem cells
- patient reported outcomes
- cell therapy
- bone marrow
- systemic sclerosis